Weak_JJ Association_NP between_IN SEN_NP Virus_NP Viremia_NP and_CC Liver_NP Disease_NP Recently_RB ,_, a_DT novel_JJ DNA_NN virus_NN designated_VBN SEN_NP virus_NN (_( SEN-V_NP )_) ,_, which_WDT is_VBZ thought_VBN to_TO be_VB related_VBN to_TO posttransfusion_NN hepatitis_NN ,_, was_VBD discovered_VBN ._SENT The_DT aim_NN of_IN the_DT present_JJ study_NN was_VBD to_TO clarify_VB the_DT relationship_NN between_IN SEN-V_NP infection_NN and_CC the_DT development_NN of_IN liver_NN disease_NN ._SENT We_PP examined_VBD SEN-V_NP from_IN the_DT sera_NN of_IN 21_CD patients_NNS with_IN non-B_NN ,_, non-C_NP hepatocellular_JJ carcinoma_NN (_( HCC_NP )_) and_CC 13_CD patients_NNS with_IN non-B_NN ,_, non-C_NP chronic_JJ liver_NN disease_NN (_( CLD_NP )_) without_IN HCC_NP who_WP were_VBD admitted_VBN to_TO our_PP$ hospital_NN between_IN 1995_CD and_CC 1997_CD ._SENT Thirty-two_NN patients_NNS without_IN liver_NN disease_NN served_VBN as_IN controls_NNS and_CC were_VBD also_RB examined_VBN for_IN SEN-V_NP ._SENT SEN-V_NP DNA_NP was_VBD detected_VBN by_IN the_DT nested_VBN PCR_NP method_NN after_IN extraction_NN of_IN DNA_NN from_IN serum_NN ._SENT SEN-V_NP DNA_NP was_VBD detected_VBN in_IN 74_CD %_NN (_( 25_CD of_IN 34_CD )_) of_IN patients_NNS with_IN CLD_NP with_IN or_CC without_IN HCC_NP who_WP were_VBD negative_JJ for_IN both_DT hepatitis_NP B_NP virus_NN surface_NN antigen_NN and_CC anti-hepatitis_NN C_NP virus_NN antibody_NN ._SENT SEN-V_NP DNA_NP was_VBD detected_VBN in_IN 69_CD %_NN (_( 9_CD of_IN 13_CD )_) of_IN CLD_NP patients_NNS without_IN HCC_NP and_CC in_IN 76_CD %_NN (_( 16_CD of_IN 21_CD )_) of_IN HCC_NP patients_NNS ._SENT The_DT prevalence_NN of_IN SEN-V_NP was_VBD no_RB higher_JJR in_IN patients_NNS with_IN liver_NN disease_NN than_IN in_IN patients_NNS without_IN liver_NN disease_NN (_( 24_CD of_IN 32_CD ;_: 75_CD %_NN )_) ._SENT There_EX were_VBD no_DT significant_JJ differences_NNS in_IN age_NN ,_, sex_NN ,_, liver_NN function_NN ,_, history_NN of_IN blood_NN transfusion_NN ,_, or_CC amount_NN of_IN alcohol_NN intake_NN between_IN SEN-V-positive_NP and_CC SEN-V-negative_NP CLD_NP and_CC HCC_NP patients_NNS ._SENT Genetic_JJ analysis_NN suggested_VBD that_IN SEN-V_NP is_VBZ closely_RB related_VBN to_TO the_DT TT_NP virus_NN family_NN ._SENT SEN-V_NP was_VBD detected_VBN at_IN almost_RB the_DT same_JJ frequency_NN in_IN patients_NNS with_IN and_CC without_IN liver_NN disease_NN ._SENT SEN-V_NP does_VBZ not_RB seem_VB to_TO contribute_VB either_RB to_TO the_DT pathogenesis_NN of_IN liver_NN disease_NN or_CC to_TO the_DT development_NN of_IN HCC_NP from_IN chronic_JJ liver_NN disease_NN ._SENT The_DT number_NN of_IN patients_NNS with_IN hepatocellular_JJ carcinoma_NN (_( HCC_NP )_) has_VBZ been_VBN increasing_VBG over_IN the_DT last_JJ 30_CD years_NNS in_IN Japan_NP ,_, and_CC approximately_RB 30,000_CD patients_NNS die_VBP of_IN HCC_NP every_DT year_NN ._SENT The_DT majority_NN of_IN these_DT patients_NNS are_VBP positive_JJ for_IN either_DT hepatitis_NP B_NP virus_NN surface_NN antigen_NN (_( HBsAg_NP )_) or_CC anti-hepatitis_NN C_NN virus_NN (_( anti-HCV_NP )_) antibody_NN ._SENT In_IN a_DT recent_JJ study_NN ,_, 11_CD %_NN of_IN HCC_NP patients_NNS were_VBD positive_JJ for_IN HBsAg_NP and_CC 84_CD %_NN were_VBD positive_JJ for_IN anti-HCV_NP ,_, but_CC the_DT remaining_VBG 4_CD %_NN were_VBD negative_JJ for_IN both_DT anti-HCV_NP and_CC HBsAg_NP ._SENT The_DT pathogenic_JJ agent_NN in_IN these_DT 4_CD %_NN of_IN patients_NNS remains_VBZ unknown_JJ ._SENT An_DT RNA_NP virus_NN associated_VBN with_IN non-A_NP to_TO E_NP hepatitis_NP named_VBD GB_NP virus_NN C_NP (GBV-C)/hepatitis_NP G_NP virus_NN (_( HGV_NP )_) and_CC a_DT DNA_NP virus_NN named_VBN TT_NP virus_NN (_( TTV_NP )_) were_VBD recently_RB cloned_VBN ._SENT However_RB ,_, previous_JJ studies_NNS showed_VBD that_IN GBV-C/HGV_NP and_CC TTV_NP are_VBP unlikely_JJ to_TO be_VB major_JJ etiologic_JJ agents_NNS of_IN non-B_NN ,_, non-C_NP HCC_NP ,_, and_CC they_PP have_VBP not_RB yet_RB been_VBN confirmed_VBN to_TO be_VB hepatotropic_JJ (_( -_: ,_, ,_, ,_, ,_, )_) ._SENT A_DT novel_JJ DNA_NN virus_NN named_VBN SEN_NP virus_NN (_( SEN-V_NP )_) was_VBD also_RB recently_RB cloned_VBN from_IN the_DT plasma_NN of_IN a_DT patient_NN with_IN posttransfusion_NN hepatitis_NN ._SENT This_DT patient_NN had_VBD elevated_VBN transaminase_NN levels_NNS but_CC did_VBD not_RB have_VB viral_JJ markers_NNS for_IN hepatitis_NN type_NN A_NP to_TO E_NP viruses_NNS or_CC hepatitis_NP G_NP virus_NN ._SENT SEN-V_NP is_VBZ a_DT circular_JJ 3,900-nucleotide_JJ DNA_NN virus_NN ._SENT There_EX are_VBP eight_CD SEN-V_NP genotypes_NNS ,_, called_VBD A_NP to_TO H._NP SEN-V_NP was_VBD classified_VBN into_IN the_DT same_JJ group_NN as_IN TTV_NP variants_NNS (_( including_VBG SANBAN_NP and_CC TUS01_NP )_) ._SENT Prototype_NN TTV_NP ,_, TTV_NP YONBAN_NP ,_, and_CC TTV_NP PMV_NP formed_VBD an_DT outer_JJ group_NN of_IN SEN-V_NP ._SENT Of_IN the_DT eight_CD genotypes_NNS ,_, genotypes_NNS D_NP and_CC H_NP (_( or_CC genotype_NN C_NN )_) have_VBP been_VBN reported_VBN to_TO be_VB related_VBN to_TO liver_NN dysfunction_NN ._SENT Although_IN SEN-V_NP has_VBZ been_VBN observed_VBN in_IN patients_NNS with_IN acute_JJ and_CC chronic_JJ liver_NN disease_NN (_( CLD_NP )_) of_IN unknown_JJ etiology_NN ,_, the_DT role_NN of_IN SEN-V_NP in_IN the_DT pathogenesis_NN of_IN liver_NN disease_NN is_VBZ not_RB yet_RB known_VBN ._SENT We_PP screened_VBD patients_NNS with_IN non-B_NN ,_, non-C_NP CLD_NP and_CC patients_NNS without_IN liver_NN disease_NN for_IN SEN-V_NP DNA_NP to_TO determine_VB the_DT possible_JJ role_NN of_IN SEN-V_NP in_IN the_DT pathogenesis_NN of_IN liver_NN disease_NN and_CC in_IN the_DT development_NN of_IN HCC_NP ,_, especially_RB in_IN patients_NNS with_IN non-B_NN ,_, non-C_NP chronic_JJ hepatitis_NP and_CC HCC_NP ._SENT Patients_NNS ._SENT |_SYM We_PP examined_VBD the_DT prevalence_NN of_IN SEN-V_NP DNA_NP in_IN 21_CD patients_NNS admitted_VBN to_TO the_DT University_NP of_IN Tokyo_NP Hospital_NP between_IN 1995_CD and_CC 1997_CD who_WP were_VBD diagnosed_VBN with_IN non-B_NN ,_, non-C_NP HCC_NP (_( the_DT HCC_NP patient_NN group_NN )_) and_CC in_IN 13_CD patients_NNS with_IN non-B_NN ,_, non-C_NP CLD_NP without_IN HCC_NP (_( the_DT CLD_NP patient_NN group_NN )_) ._SENT Thirty-two_NN patients_NNS without_IN liver_NN disease_NN were_VBD also_RB examined_VBN and_CC served_VBN as_IN a_DT control_NN group_NN ._SENT These_DT patients_NNS presented_VBN to_TO our_PP$ hospital_NN with_IN abdominal_JJ complaints_NNS but_CC had_VBD normal_JJ transaminase_NN levels_NNS ._SENT The_DT diagnosis_NN of_IN HCC_NP was_VBD made_VBN by_IN ultrasonography_NN ,_, computed_VBN tomography_NN ,_, magnetic_JJ resonance_NN imaging_NN ,_, angiography_NN ,_, and_CC liver_NN biopsy_NN ._SENT The_DT clinical_JJ features_NNS examined_VBD included_VBN age_NN ,_, sex_NN ,_, history_NN of_IN blood_NN transfusion_NN ,_, history_NN of_IN alcohol_NN intake_NN ,_, serum_NN transaminase_NN levels_NNS ,_, platelet_NN count_NN ,_, and_CC indocyanine_NN green_NN (_( ICG_NP )_) retention_NN rate_NN (_( percent_NN )_) at_IN 15_CD min_NN (_( the_DT ICG_NP R15_NP test_NN )_) ._SENT Anti-HCV_NP was_VBD identified_VBN by_IN a_DT second-generation_NN enzyme_NN immunoassay_NN (_( Ortho_NP Diagnostics_NP ,_, Tokyo_NP ,_, Japan_NP )_) ,_, and_CC HBsAg_NP was_VBD identified_VBN by_IN radioimmunoassay_NP (_( Abbott_NP Laboratories_NP ,_, North_NP Chicago_NP ,_, Ill._NP )_) ._SENT Patients_NNS with_IN an_DT ethanol_NN intake_NN exceeding_VBG 80_CD g/day_NN for_IN more_JJR than_IN 10_CD years_NNS were_VBD considered_VBN to_TO have_VB a_DT positive_JJ history_NN for_IN alcohol_NN abuse_NN ._SENT Patients_NNS who_WP were_VBD positive_JJ for_IN antinuclear_JJ antibody_NN or_CC anti-smooth_NN muscle_NN antibody_NN or_CC who_WP had_VBD a_DT positive_JJ lupus_NN erythematosus_NN test_NN result_NN were_VBD excluded_VBN ._SENT Patients_NNS who_WP had_VBD previously_RB been_VBN treated_VBN with_IN antiviral_JJ drugs_NNS ,_, such_JJ as_IN interferon_NN and_CC lamivudine_NP ,_, were_VBD also_RB excluded_VBN ._SENT Serum_NN samples_NNS from_IN all_DT patients_NNS with_IN HCC_NP were_VBD obtained_VBN at_IN the_DT first_JJ admission_NN after_IN the_DT diagnosis_NN of_IN HCC_NP ._SENT The_DT serum_NN samples_NNS were_VBD stored_VBN at_IN -30C_NN ._SENT Detection_NN of_IN SEN-V_NP DNA_NP ._SENT |_SYM DNA_NN was_VBD extracted_VBN from_IN 50_CD mul_NN of_IN serum_NN with_IN the_DT SepaGene_NP kit_NN (_( Sanko_NP Junyaku_NP ,_, Tokyo_NP ,_, Japan_NP )_) according_VBG to_TO the_DT manufacturer_NN 's_POS instructions_NNS ._SENT The_DT extracted_VBN DNA_NN was_VBD dissolved_VBN in_IN 20_CD mul_NN of_IN Tris-HCl_NP buffer_NN (_( 10_CD mM_NNS ;_: pH_NN 8.0_CD )_) containing_VBG 1_CD mM_NP EDTA_NP ,_, heated_VBN to_TO 95C_NN for_IN 15_CD min_NN ,_, and_CC quickly_RB chilled_VBN on_IN ice_NN ._SENT The_DT total_JJ amount_NN of_IN extracted_VBN DNA_NN was_VBD subjected_VBN to_TO nested_VBN PCR_NP with_IN Ready-To-Go_NP PCR_NP beads_NNS (_( Pharmacia_NP Biotech_NP ,_, Uppsala_NP ,_, Sweden_NP )_) ._SENT The_DT first_JJ round_NN of_IN PCR_NP was_VBD performed_VBN with_IN primer_JJR sets_NNS specific_JJ for_IN each_DT genotype_NN ._SENT The_DT sense_NN primers_NNS specific_JJ for_IN genotypes_NNS A_DT to_TO D_NP and_CC H_NP were_VBD as_RB follows_VBZ :_: SEA-S_NP ,_, SEB-S_NP ,_, SEC-S_NP ,_, SED-S_NP ,_, and_CC SEH-S_NP ,_, respectively_RB ._SENT The_DT antisense_NN primers_NNS specific_JJ for_IN genotypes_NNS A_DT to_TO D_NP and_CC H_NP were_VBD as_RB follows_VBZ :_: SEA-AS_NP ,_, SEB-AS_NP ,_, SEC-AS_NP ,_, SED-AS_NP ,_, and_CC SEH-AS_NP ,_, respectively_RB ._SENT These_DT primers_NNS were_VBD used_VBN to_TO amplify_VB 336-_CD ,_, 444-_CD ,_, 619-_CD ,_, 510-_CD ,_, and_CC 830-bp_JJ fragments_NNS from_IN genotypes_NNS A_DT to_TO D_NP and_CC H_NP ,_, respectively_RB ._SENT The_DT reaction_NN was_VBD run_VBN in_IN microtubes_NNS with_IN the_DT GeneAmp_NP PCR_NP system_NN 9600_CD (_( Perkin-Elmer_NP Applied_NP Biosystems_NP ,_, Foster_NP City_NP ,_, Calif._NP )_) ._SENT Amplification_NN was_VBD performed_VBN for_IN 35_CD cycles_NNS ,_, with_IN each_DT cycle_NN consisting_VBG of_IN denaturation_NN at_IN 94C_NN for_IN 1_CD min_NN ,_, annealing_VBG at_IN 54C_NN for_IN 1_CD min_NN ,_, and_CC elongation_NN at_IN 72C_NP for_IN 1_CD min_NN ._SENT A_DT 10-min_JJ final_JJ hold_NN at_IN 72C_NP was_VBD used_VBN to_TO complete_VB strand_NN synthesis_NN ._SENT The_DT second_JJ round_NN of_IN PCR_NP was_VBD carried_VBN out_RP with_IN sense_NN and_CC antisense_NN primers_NNS specific_JJ for_IN genotypes_NNS A_DT to_TO D_NP and_CC H._NP The_DT sense_NN primers_NNS were_VBD as_RB follows_VBZ :_: SEA-S2_NP ,_, SEB-S2_NP ,_, SEC-S2_NP ,_, SED-S2_NP ,_, and_CC SEH-S2_NP ,_, respectively_RB ._SENT The_DT antisense_NN primers_NNS specific_JJ for_IN genotypes_NNS A_DT to_TO D_NP and_CC H_NP were_VBD as_RB follows_VBZ :_: SEA-AS2_NP ,_, SEB-AS2_NP ,_, SEC-AS2_NP ,_, SED-AS2_NP ,_, and_CC SEH-AS2_NP ,_, respectively_RB ._SENT These_DT primers_NNS were_VBD used_VBN to_TO amplify_VB 288-_CD ,_, 396-_CD ,_, 577-_CD ,_, 459-_CD ,_, and_CC 783-bp_JJ fragments_NNS from_IN genotypes_NNS A_DT to_TO D_NP and_CC H_NP ,_, respectively_RB ._SENT The_DT amplification_NN was_VBD performed_VBN for_IN 30_CD cycles_NNS ,_, with_IN each_DT cycle_NN consisting_VBG of_IN denaturation_NN at_IN 94C_NN for_IN 1_CD min_NN ,_, annealing_VBG at_IN 54C_NN for_IN 1_CD min_NN ,_, and_CC elongation_NN at_IN 72C_NP for_IN 1_CD min_NN ,_, followed_VBN by_IN a_DT final_JJ hold_NN at_IN 72C_NP for_IN 7_CD min_NN ._SENT The_DT amplified_VBN products_NNS were_VBD electrophoresed_VBN on_IN 1.5_CD %_NN agarose_NN gels_NNS ,_, stained_VBN with_IN ethidium_NN bromide_NN ,_, and_CC observed_VBD under_IN UV_NP light_NN ._SENT Detection_NN of_IN SEN-V_NP in_IN DNA_NP from_IN human_JJ WBCs_NP ._SENT |_SYM To_TO exclude_VB the_DT possibility_NN that_IN we_PP had_VBD amplified_VBN the_DT host_NN genome_NN by_IN PCR_NP ,_, we_PP compared_VBD the_DT detectabilities_NNS of_IN SEN-V_NP DNA_NP from_IN sera_NN and_CC from_IN white_JJ blood_NN cells_NNS (_( WBCs_NP )_) ._SENT We_PP chose_VBD four_CD patients_NNS and_CC four_CD controls_NNS (_( two_CD patients_NNS each_DT had_VBD SEN-V_NP type_NN D-_NP and_CC SEN-V_NP type_NN H-positive_JJ sera_NN ,_, and_CC two_CD controls_NNS each_DT had_VBD SEN-V_NP type_NN D-_NP and_CC SEN-V_NP type_NN H-negative_JJ sera_NN )_) and_CC extracted_VBD WBC_NP DNA_NP from_IN all_DT of_IN them_PP ._SENT Each_DT pair_NN of_IN samples_NNS was_VBD randomly_RB chosen_VBN from_IN groups_NNS of_IN patients_NNS whose_WP$ sera_NN had_VBD the_DT same_JJ SEN-V_NP infection_NN status_NN ._SENT DNA_NP was_VBD extracted_VBN from_IN 3_CD ml_NN of_IN whole_JJ blood_NN with_IN the_DT SepaGene_NP kit_NN (_( Sanko_NP Junyaku_NP ,_, Tokyo_NP ,_, Japan_NP )_) according_VBG to_TO the_DT instructions_NNS of_IN the_DT manufacturer_NN ._SENT The_DT extracted_VBN DNA_NN was_VBD dissolved_VBN in_IN 20_CD mul_NN of_IN Tris-HCl_NP buffer_NN (_( 10_CD mM_NNS ;_: pH_NN 8.0_CD )_) containing_VBG 1_CD mM_NP EDTA_NP ,_, heated_VBN to_TO 95C_NN for_IN 15_CD min_NN ,_, and_CC quickly_RB chilled_VBN on_IN ice_NN ._SENT The_DT total_JJ amount_NN of_IN extracted_VBN DNA_NN was_VBD subjected_VBN to_TO nested_VBN PCR_NP ._SENT We_PP tried_VBD to_TO detect_VB SEN-V_NP DNA_NP in_IN sera_NN and_CC WBCs_NP by_IN PCR_NP ,_, using_VBG the_DT same_JJ primers_NNS and_CC protocol_NN and_CC under_IN the_DT same_JJ conditions_NNS ._SENT Genetic_JJ analysis_NN of_IN SEN-V_NP DNA_NP ._SENT |_SYM Nucleotide_NN sequencing_VBG of_IN detectable_JJ SEN-V_NP DNA_NP was_VBD performed_VBN with_IN an_DT autosequencer_NN (_( Perkin-Elmer_NP Applied_NP Biosystems_NP ,_, Foster_NP City_NP ,_, Calif._NP )_) and_CC the_DT dye_NN termination_NN method_NN as_RB described_VBD previously_RB ._SENT The_DT direct_JJ sequencing_NP reactions_NNS were_VBD carried_VBN out_RP with_IN primers_NNS specific_JJ for_IN genotypes_NNS D_NP and_CC H_NP :_: SED-S3_NP and_CC SEH-S3_NP ,_, respectively_RB ._SENT The_DT sequences_NNS of_IN SEN-V_NP types_NNS D_NP and_CC H_NP were_VBD compared_VBN to_TO the_DT prototype_NN sequences_NNS of_IN SEN-V_NP (_( SEN-V_NP type_NN D_NP ,_, nucleotides_NNS 528_CD to_TO 677_CD ;_: SEN-V_NP type_NN H_NN ,_, nucleotides_NNS 402_CD to_TO 551_CD )_) or_CC the_DT reported_VBN sequence_NN of_IN TTV_NP (_( TTV_NP nucleotides_NNS 701_CD to_TO 850_CD and_CC TTV_NP nucleotides_NNS 401_CD to_TO 550_CD )_) ._SENT A_DT phylogenetic_JJ tree_NN was_VBD constructed_VBN by_IN the_DT unweighted_JJ pair_NN group_NN method_NN with_IN the_DT arithmetic_JJ mean_NN with_IN the_DT computer_NN software_NN package_NN GENETYX-MAC_NP (_( Software_NP Development_NP Co._NP ,_, Ltd._NP ,_, Tokyo_NP ,_, Japan_NP )_) ._SENT Nucleotide_NN sequence_NN homologies_NNS among_IN the_DT SEN-V_NP DNAs_NP obtained_VBD from_IN patients_NNS and_CC controls_NNS were_VBD calculated_VBN and_CC analyzed_VBN ._SENT In_IN order_NN to_TO identify_VB the_DT full-length_JJ nucleotide_NN sequence_NN ,_, fragments_NNS of_IN SEN-V_NP types_NNS D_NP and_CC H_NP were_VBD amplified_VBN with_IN the_DT following_VBG PCR_NP primer_NN sets_NNS :_: SED_NN Full_NP F_NP and_CC SED(1)_NP R_NP ,_, SED_NN S2_NN and_CC SED_NN AS2_NN ,_, SED(3)_NP F_NP and_CC SED(3)_NP R_NP ,_, SED(4)_NP F_NP and_CC SED(4)_NP R_NP ,_, SED(5)_NP F_NP and_CC SED(5)_NP R_NP ,_, and_CC SED(6)_NP F_NN and_CC SED_NN Full_JJ R_NN and_CC primer_NN sets_VBZ SEH_NP Full_NP F_NP and_CC SEH(1)_NP R_NP ,_, SEH_NP S2_NP and_CC SEH_NP AS2_NP ,_, SEH(3)_NP F_NP and_CC SEH(3)_NP R_NP ,_, SEH(4)_NP F_NP and_CC SEH(4)_NP R_NP ,_, SEH(5)_NP F_NP and_CC SEH(5)_NP R_NP ,_, and_CC SEH(6)_NP F_NP and_CC SEH_NP Full_NP R_NP ._SENT Each_DT primer_NN set_NN was_VBD designed_VBN to_TO amplify_VB one_CD of_IN six_CD fragments_NNS from_IN SEN-V_NP type_NN D_NP (_( nucleotides_NNS 1_CD to_TO 553_CD ,_, 495_CD to_TO 953_CD ,_, 868_CD to_TO 1589_CD ,_, 1439_CD to_TO 2082_CD ,_, 1990_CD to_TO 2688_CD ,_, and_CC 2632_CD to_TO 3264_CD )_) or_CC one_CD of_IN six_CD fragments_NNS from_IN SEN-V_NP type_NN H_NN (_( nucleotides_NNS 1_CD to_TO 446_CD ,_, 381_CD to_TO 1163_CD ,_, 904_CD to_TO 1593_CD ,_, 1376_CD to_TO 2163_CD ,_, 1975_CD to_TO 2558_CD ,_, and_CC 2480_CD to_TO 3292_CD )_) ._SENT The_DT full-length_JJ nucleotide_NN sequence_NN was_VBD identified_VBN by_IN direct_JJ sequencing_VBG with_IN each_DT set_NN of_IN sense_NN and_CC antisense_NN primers_NNS ._SENT The_DT codon_NN distributions_NNS and_CC hydrophobicities_NNS of_IN the_DT polyproteins_NNS encoded_VBN by_IN the_DT open_JJ reading_NN frames_NNS (_( ORFs_NP )_) of_IN SEN-V_NP types_NNS D_NP and_CC H_NP were_VBD analyzed_VBN ._SENT Statistical_JJ analysis_NN ._SENT |_SYM The_DT results_NNS are_VBP expressed_VBN as_IN the_DT means_NN +-_NN standard_NN deviations_NNS ._SENT Comparisons_NNS were_VBD performed_VBN by_IN Student_NP 's_POS t_NN test_NN and_CC the_DT chi-square_NN test_NN ._SENT Fisher_NP 's_POS exact_JJ probability_NN test_NN was_VBD used_VBN to_TO examine_VB the_DT relationship_NN between_IN HCC_NP and_CC SEN-V_NP ._SENT A_DT P_NN value_NN of_IN less_JJR than_IN 0.05_CD was_VBD considered_VBN statistically_RB significant_JJ ._SENT Nucleotide_NN sequence_NN accession_NN numbers_NNS ._SENT |_SYM The_DT two_CD full-length_JJ nucleotide_NN sequences_NNS of_IN SEN-V_NP identified_VBN from_IN a_DT CLD_NP patient_NN (_( type_NN D_NP )_) and_CC a_DT control_NN (_( type_NN H_NN )_) have_VBP been_VBN submitted_VBN to_TO the_DT DDBJ_NP database_NN and_CC given_VBN accession_NN numbers_NNS and_CC ,_, respectively_RB ._SENT TABLE_NN 1_CD |_SYM Primers_NP used_VBN to_TO detect_VB or_CC sequence_NN SEN-V_NP Incidence_NN of_IN SEN-V_NP DNA_NP in_IN HCC_NP and_CC CLD_NP patients_NNS ._SENT |_SYM SEN-V_NP DNA_NP was_VBD detected_VBN in_IN 25_CD of_IN 34_CD (_( 74_CD %_NN )_) patients_NNS with_IN non-B_NN ,_, non-C_NP CLD_NP ,_, 9_CD of_IN 13_CD (_( 69_CD %_NN )_) patients_NNS with_IN CLD_NP ,_, and_CC 16_CD of_IN 21_CD (_( 76_CD %_NN )_) patients_NNS with_IN HCC_NP ._SENT SEN-V_NP DNA_NP was_VBD detected_VBN in_IN 24_CD of_IN 32_CD (_( 75_CD %_NN )_) controls_VBZ ._SENT The_DT incidence_NN of_IN SEN-V_NP was_VBD not_RB significantly_RB different_JJ between_IN patients_NNS and_CC controls_NNS or_CC between_IN patients_NNS with_IN HCC_NP and_CC patients_NNS with_IN CLD_NP but_CC without_IN HCC_NP ._SENT Clinical_JJ features_NNS of_IN SEN-V-positive_JJ chronic_JJ hepatitis_NN and_CC HCC_NP patients_NNS ._SENT |_SYM The_DT clinical_JJ features_NNS of_IN the_DT patients_NNS with_IN HCC_NP and_CC the_DT patients_NNS with_IN CLD_NP but_CC without_IN HCC_NP with_IN respect_NN to_TO SEN-V_NP infection_NN status_NN are_VBP shown_VBN in_IN Table_NP ._SENT The_DT clinical_JJ features_NNS included_VBD age_NN ;_: sex_NN ;_: serum_NN albumin_NN ,_, total_JJ bilirubin_NN ,_, and_CC transaminase_NN levels_NNS ;_: the_DT results_NNS of_IN the_DT ICG_NP R15_NP test_NN ;_: platelet_NN count_NN ;_: blood_NN transfusion_NN history_NN ;_: and_CC a_DT history_NN of_IN heavy_JJ alcohol_NN intake_NN ._SENT There_EX were_VBD no_DT statistically_RB significant_JJ differences_NNS in_IN these_DT clinical_JJ features_NNS between_IN SEN-V-positive_JJ and_CC SEN-V-negative_JJ patients_NNS ._SENT There_EX were_VBD no_DT significant_JJ differences_NNS in_IN tumor_NN markers_NNS ,_, such_JJ as_IN alpha-fetoprotein_NN and_CC des-gamma-carboxyprothrombin_NN levels_NNS ,_, or_CC in_IN tumor_NN factors_NNS (_( size_NN ,_, tumor-node-metastasis_NN classification_NN )_) between_IN SEN-V-positive_NP and_CC SEN-V-negative_NP HCC_NP patients_NNS (_( data_NNS not_RB shown_VBN )_) ._SENT A_DT background_NN liver_NN biopsy_NN specimen_NN was_VBD obtained_VBN from_IN 12_CD of_IN 16_CD SEN-V-positive_JJ HCC_NP patients_NNS ._SENT Of_IN the_DT 12_CD SEN-V-positive_JJ HCC_NP patients_NNS ,_, 5_CD (_( 42_CD %_NN )_) had_VBD chronic_JJ hepatitis_NN and_CC 6_CD (_( 50_CD %_NN )_) had_VBD cirrhosis_NN ._SENT A_DT background_NN liver_NN biopsy_NN specimen_NN was_VBD obtained_VBN from_IN four_CD of_IN the_DT five_CD SEN-V-negative_JJ HCC_NP patients_NNS ._SENT Of_IN the_DT four_CD SEN-V-negative_JJ HCC_NP patients_NNS ,_, one_CD (_( 25_CD %_NN )_) had_VBD chronic_JJ hepatitis_NN and_CC three_CD (_( 75_CD %_NN )_) had_VBD cirrhosis_NN ._SENT The_DT fibrotic_JJ stage_NN of_IN background_NN liver_NN disease_NN was_VBD not_RB significantly_RB different_JJ between_IN SEN-V-positive_JJ and_CC SEN-V-negative_JJ patients_NNS ,_, irrespective_RB of_IN HCC_NP status_NN (_( P_NN =_SYM 0.89_CD )_) ._SENT Both_CC the_DT serum_NN and_CC the_DT WBCs_NP of_IN only_RB one_CD of_IN four_CD SEN-V-positive_JJ patients_NNS and_CC controls_NNS were_VBD SEN-V_NP type_NN D_NP positive_NN ._SENT However_RB ,_, the_DT WBCs_NP of_IN none_NN of_IN the_DT patients_NNS or_CC controls_NNS who_WP were_VBD SEN-V_NP negative_NN were_VBD SEN-V_NP positive_NN ._SENT Genetic_JJ analysis_NN of_IN SEN-V_NP DNA_NP ._SENT |_SYM Most_JJS of_IN the_DT SEN-V_NP DNA_NN sequences_NNS varied_VBN between_IN patients_NNS ,_, to_TO the_DT extent_NN that_IN we_PP examined_VBD them_PP ._SENT D1-13_NP and_CC H11-18_NP were_VBD SEN-V_NP DNAs_NP obtained_VBD from_IN the_DT sera_NN of_IN controls_NNS ,_, D15-30_NP and_CC H20-45_NP were_VBD from_IN the_DT sera_NN of_IN HCC_NP patients_NNS ,_, and_CC D31-59_NP and_CC H53-66_NP were_VBD from_IN the_DT sera_NN of_IN CLD_NP patients_NNS without_IN HCC_NP ._SENT There_EX were_VBD no_DT specific_JJ regions_NNS where_WRB mutations_NNS accumulated_VBD ._SENT All_PDT the_DT samples_NNS from_IN SEN-V_NP type_NN D-_NN and_CC H-positive_JJ patients_NNS that_WDT were_VBD sequenced_VBN were_VBD classified_VBN by_IN genotype_NN according_VBG to_TO the_DT genetic_JJ analysis_NN shown_VBN in_IN the_DT phylogenetic_JJ tree_NN ._SENT Each_DT genotype-specific_JJ primer_NN worked_VBD as_RB expected_VBN ._SENT All_DT of_IN the_DT clones_NNS of_IN SEN-V_NP types_NNS D_NP and_CC H_NP obtained_VBD were_VBD classified_VBN as_IN closely_RB related_VBN to_TO the_DT TTV_NP family_NN ._SENT The_DT nucleotide_NN sequence_NN homologies_NNS among_IN the_DT SEN-V_NP DNAs_NP obtained_VBD from_IN patients_NNS and_CC controls_NNS were_VBD calculated_VBN ._SENT The_DT nucleotide_NN sequence_NN homologies_NNS were_VBD 80_CD to_TO 100_CD %_NN (_( mean_VB +-_JJ standard_JJ deviation_NN ,_, 93_CD %_NN +-_NN 5_CD %_NN )_) among_IN SEN-V_NP type_NN D_NP DNAs_NP and_CC 85_CD to_TO 97_CD %_NN (_( 91_CD %_NN +-_NN 4_CD %_NN )_) among_IN SEN-V_NP type_NN H_NP DNAs_NP ._SENT Two_CD SEN-V_NP type_NN D_NN genomes_NNS and_CC one_CD SEN-V_NP type_NN H_NN genome_NN showed_VBD comparatively_RB low_JJ levels_NNS of_IN homology_NN with_IN other_JJ sequences_NNS ,_, but_CC there_EX were_VBD no_DT significant_JJ differences_NNS among_IN the_DT sequences_NNS of_IN SEN-V_NP DNA_NP from_IN controls_NNS ,_, HCC_NP patients_NNS ,_, and_CC CLD_NP patients_NNS without_IN HCC_NP ._SENT Two_CD full-length_JJ nucleotide_NN sequences_NNS of_IN SEN-V_NP were_VBD identified_VBN from_IN a_DT CLD_NP patient_NN and_CC a_DT control_NN ._SENT One_PP was_VBD type_NN D_NN and_CC the_DT other_JJ was_VBD type_NN H._NN These_DT sequences_NNS had_VBD high_JJ degrees_NNS of_IN homology_NN with_IN the_DT sequences_NNS reported_VBN for_IN SEN-V_NP type_NN D_NP and_CC H_NP DNAs_NP (_( data_NN not_RB shown_VBN )_) ._SENT The_DT codon_NN distribution_NN and_CC hydrophobicity_NN profile_NN within_IN the_DT ORFs_NP (_( SEN-V_NP type_NN D_NP ,_, nucleotides_NNS 252_CD to_TO 725_CD ;_: SEN-V_NP type_NN H_NN ,_, nucleotides_NNS 256_CD to_TO 723_CD )_) of_IN the_DT SEN-V_NP DNAs_NP obtained_VBD and_CC reported_VBD were_VBD analyzed_VBN ._SENT Differences_NNS in_IN codon_NN usage_NN between_IN the_DT SEN-V_NP DNAs_NP obtained_VBD and_CC reported_VBD were_VBD observed_VBN for_IN 17_CD SEN-V_NP type_NN D_NN codons_NNS and_CC 18_CD SEN-V_NP type_NN H_NN codons_NNS ._SENT The_DT hydrophobicity_NN profiles_NNS of_IN amino_NN acids_NNS 100_CD to_TO 110_CD of_IN the_DT SEN-V_NP D_NP type_NN ORF_NP and_CC amino_NN acids_NNS 90_CD to_TO 100_CD of_IN the_DT SEN-V_NP type_NN H_NP ORF_NP differed_VBD from_IN those_DT reported_VBN for_IN SEN-V_NP types_NNS D_NP and_CC H._NP FIG._NN 1_CD ._SENT |_SYM Multiple-sequence_NN alignments_NNS of_IN SEN-V_NP DNAs_NP ._SENT Multiple-sequence_NN alignments_NNS of_IN SEN-V_NP DNAs_NP ._SENT The_DT sequences_NNS of_IN the_DT samples_NNS were_VBD compared_VBN with_IN the_DT consensus_NN sequence_NN ._SENT Only_RB the_DT nucleotides_NNS that_WDT differed_VBD from_IN the_DT consensus_NN sequence_NN are_VBP shown_VBN ._SENT SEN-V_NP type_NN D_NP nucleotides_NNS 528_CD to_TO 677_CD and_CC SEN-V_NP type_NN H_NN nucleotides_NNS 402_CD to_TO 551_CD are_VBP the_DT consensus_NN sequences_NNS ._SENT D1_NP ,_, D6_NP ,_, D8_NP ,_, D10_NP ,_, D12_NP ,_, D13_NP ,_, D15_NP ,_, D16_NP ,_, D17_NP ,_, D23_NP ,_, D25_NP ,_, D29_NP ,_, D30_NP ,_, D31_NP ,_, D32_NP ,_, and_CC D59_NP and_CC H11_NP ,_, H14_NP ,_, H18_NP ,_, H20_NP ,_, H22_NP ,_, H45_NP ,_, H53_NP ,_, and_CC H66_NP are_VBP samples_NNS from_IN patients_NNS (_( HCC_NP ,_, CLD_NP )_) and_CC controls_VBZ (_( CNTL_NP )_) ._SENT FIG._NN 2_CD ._SENT |_SYM Nucleotides_NP 528_CD to_TO 677_CD of_IN SEN-V_NP type_NN D_NP were_VBD compared_VBN with_IN the_DT sequences_NNS of_IN the_DT same_JJ regions_NNS of_IN SEN-V_NP types_NNS A_NP to_TO H_NP and_CC TTV_NP nucleotides_NNS 701_CD to_TO 850_CD ._SENT Nucleotides_NNS 528_CD to_TO 677_CD of_IN SEN-V_NP type_NN D_NP were_VBD compared_VBN with_IN the_DT sequences_NNS of_IN the_DT same_JJ regions_NNS of_IN SEN-V_NP types_NNS A_NP to_TO H_NP and_CC TTV_NP nucleotides_NNS 701_CD to_TO 850_CD ._SENT Nucleotides_NNS 402_CD to_TO 551_CD of_IN SEN-V_NP type_NN H_NN were_VBD compared_VBN with_IN the_DT sequences_NNS of_IN the_DT same_JJ regions_NNS of_IN SEN-V_NP types_NNS A_NP to_TO H_NP and_CC TTV_NP nucleotides_NNS 402_CD to_TO 551_CD ._SENT The_DT phylogenetic_JJ tree_NN was_VBD constructed_VBN by_IN the_DT unweighted_JJ pair_NN group_NN method_NN with_IN the_DT arithmetic_JJ mean_NN by_IN using_VBG the_DT computer_NN software_NN package_NN GENETYX-MAC_NP (_( Software_NP Development_NP Co._NP ,_, Ltd._NP )_) ._SENT The_DT sample_NN numbers_NNS are_VBP as_RB described_VBN in_IN the_DT legend_NN to_TO Fig._NN ._SENT TABLE_NN 2_CD |_SYM Clinical_JJ features_NNS of_IN patients_NNS Since_IN the_DT discovery_NN of_IN HCV_NP ,_, it_PP has_VBZ become_VBN obvious_JJ that_IN this_DT virus_NN causes_VBZ the_DT majority_NN of_IN cases_NNS of_IN non-A_NP ,_, non-B_NN CLD_NP ,_, including_VBG cirrhosis_NN and_CC HCC_NP ._SENT However_RB ,_, the_DT causative_JJ agent_NN of_IN non-B_NN ,_, non-C_NP CLD_NP remains_VBZ unknown_JJ ._SENT Recently_RB ,_, the_DT discovery_NN of_IN SEN-V_NP ,_, a_DT novel_JJ DNA_NN virus_NN associated_VBN with_IN posttransfusion_NN hepatitis_NN ,_, was_VBD reported_VBN ._SENT The_DT prevalence_NN of_IN SEN-V_NP in_IN our_PP$ study_NN group_NN of_IN patients_NNS with_IN HCC_NP or_CC patients_NNS with_IN CLD_NP without_IN HCC_NP is_VBZ similar_JJ to_TO the_DT prevalences_NNS reported_VBN in_IN previous_JJ studies_NNS ,_, in_IN which_WDT SEN-V_NP DNA_NP was_VBD detected_VBN in_IN 17_CD to_TO 92_CD %_NN of_IN patients_NNS with_IN liver_NN disease_NN (_( ,_, -_: )_) ._SENT However_RB ,_, our_PP$ study_NN showed_VBD a_DT high_JJ prevalence_NN of_IN SEN-V_NP in_IN controls_NNS ,_, in_IN contrast_NN to_TO the_DT low_JJ prevalence_NN (_( 1_CD to_TO 10_CD %_NN )_) in_IN subjects_NNS without_IN liver_NN disease_NN reported_VBN in_IN previous_JJ studies_NNS ._SENT The_DT difference_NN in_IN the_DT rate_NN of_IN detection_NN of_IN SEN-V_NP DNA_NP between_IN this_DT and_CC previous_JJ reports_NNS may_MD be_VB due_JJ to_TO differences_NNS in_IN the_DT quantity_NN of_IN SEN-V_NP DNA_NP in_IN the_DT sera_NN ,_, differences_NNS in_IN the_DT PCR_NP primers_NNS used_VBD ,_, or_CC differences_NNS in_IN the_DT sensitivities_NNS of_IN the_DT assay_NN systems_NNS used_VBD ._SENT According_VBG to_TO the_DT results_NNS of_IN sequence_NN analysis_NN ,_, the_DT specificity_NN of_IN the_DT PCR_NP was_VBD high_JJ enough_RB ._SENT The_DT sensitivity_NN of_IN the_DT PCR_NP could_MD not_RB be_VB determined_VBN accurately_RB because_IN the_DT concentration_NN of_IN SEN-V_NP DNA_NP varied_VBD among_IN samples_NNS ._SENT The_DT high_JJ rate_NN of_IN detection_NN of_IN SEN-V_NP DNA_NP in_IN sera_NN from_IN healthy_JJ controls_NNS may_MD indicate_VB a_DT high_JJ prevalence_NN of_IN SEN-V_NP ._SENT To_TO eliminate_VB the_DT possibility_NN that_IN we_PP were_VBD detecting_VBG human_JJ genome_NN sequences_NNS ,_, we_PP performed_VBD PCR_NP using_VBG WBC_NP DNA_NP as_IN a_DT template_NN ._SENT We_PP also_RB compared_VBD the_DT detectabilities_NNS of_IN SEN-V_NP DNA_NP from_IN sera_NN and_CC from_IN WBCs_NP ._SENT WBCs_NNS from_IN none_NN of_IN the_DT SEN-V-negative_JJ patients_NNS was_VBD SEN-V_NP DNA_NP positive_NN ._SENT If_IN the_DT SEN-V_NP DNA_NP detected_VBD originated_VBN in_IN the_DT human_JJ genome_NN ,_, it_PP should_MD mainly_RB be_VB detected_VBN in_IN WBCs_NP rather_RB than_IN in_IN serum_NN ._SENT Furthermore_RB ,_, the_DT sequences_NNS of_IN the_DT DNAs_NP that_IN we_PP amplified_VBD varied_VBN among_IN the_DT patients_NNS ._SENT The_DT DNA_NN sequences_NNS obtained_VBN from_IN SEN-V_NP type_NN D-_NN and_CC type_NN H-positive_JJ patients_NNS were_VBD classified_VBN by_IN genotype_NN ,_, and_CC those_DT from_IN SEN-V_NP type_NN A_NP to_TO C-positive_NP and_CC SEN-V_NP type_NN E_NN to_TO G-positive_JJ patients_NNS were_VBD classified_VBN in_IN the_DT phylogenetic_JJ tree_NN ._SENT The_DT intragenotype_NN homologies_NNS between_IN the_DT sequences_NNS obtained_VBN from_IN our_PP$ patients_NNS and_CC those_DT reported_VBD for_IN SEN-V_NP DNA_NP were_VBD at_IN least_JJS 87_CD %_NN (_( SEN-V_NP type_NN D_NP )_) and_CC 90_CD %_NN (_( SEN-V_NP type_NN H_NN )_) ._SENT These_DT results_NNS suggest_VBP that_IN the_DT DNA_NN that_IN we_PP detected_VBD was_VBD viral_JJ DNA_NN rather_RB than_IN DNA_NN from_IN the_DT host_NN genome_NN ._SENT We_PP also_RB investigated_VBD whether_IN there_EX was_VBD a_DT correlation_NN between_IN the_DT presence_NN of_IN SEN-V_NP and_CC the_DT severity_NN of_IN CLD_NP with_IN concomitant_JJ HCC_NP ._SENT Infection_NN with_IN SEN-V_NP did_VBD not_RB have_VB a_DT significant_JJ effect_NN on_IN the_DT status_NN of_IN liver_NN disease_NN ._SENT The_DT prevalence_NN of_IN SEN-V_NP DNA_NP viremia_NN in_IN our_PP$ study_NN was_VBD similar_JJ in_IN patients_NNS with_IN HCC_NP (_( 76_CD %_NN )_) and_CC patients_NNS with_IN CLD_NP without_IN HCC_NP (_( 69_CD %_NN )_) ._SENT Thus_RB ,_, SEN-V_NP does_VBZ not_RB seem_VB to_TO contribute_VB to_TO the_DT development_NN of_IN CLD_NP or_CC the_DT development_NN of_IN HCC_NP from_IN CLD_NP ._SENT The_DT prevalence_NN of_IN TTV_NP in_IN this_DT study_NN was_VBD lower_JJR than_IN that_IN reported_VBN previously_RB ._SENT The_DT difference_NN in_IN the_DT PCR_NP primers_NNS used_VBD to_TO detect_VB the_DT TTV_NP DNA_NP could_MD explain_VB the_DT lower_JJR prevalence_NN of_IN TTV_NP in_IN our_PP$ study_NN ._SENT Genetic_JJ analysis_NN of_IN the_DT SEN-V_NP DNA_NN sequences_NNS obtained_VBN showed_VBD no_DT differences_NNS among_IN the_DT control_NN ,_, HCC_NP ,_, and_CC CLD_NP without_IN HCC_NP groups_NNS ._SENT In_IN the_DT analysis_NN of_IN full-length_JJ SEN-V_NP type_NN D_NP and_CC H_NP DNAs_NP ,_, we_PP found_VBD slight_JJ differences_NNS in_IN codon_NN distributions_NNS and_CC hydrophobicities_NNS ._SENT In_IN order_NN to_TO estimate_VB whether_IN these_DT differences_NNS are_VBP significant_JJ ,_, we_PP must_MD compare_VB more_JJR sequences_NNS from_IN strains_NNS of_IN the_DT same_JJ genotypes_NNS ._SENT On_IN the_DT basis_NN of_IN the_DT results_NNS of_IN this_DT study_NN ,_, it_PP is_VBZ unlikely_JJ that_IN SEN-V_NP contributes_VBZ to_TO the_DT incidence_NN of_IN liver_NN disease_NN or_CC the_DT development_NN of_IN HCC_NP in_IN Japan_NP ._SENT However_RB ,_, a_DT prospective_JJ study_NN of_IN the_DT incidence_NN of_IN HCC_NP in_IN a_DT large_JJ population_NN of_IN SEN-V-positive_JJ and_CC -negative_JJ patients_NNS will_MD be_VB required_VBN to_TO prove_VB whether_IN SEN-V_NP contributes_VBZ to_TO the_DT increasing_VBG tendency_NN of_IN chronic_JJ liver_NN disease_NN to_TO progress_VB to_TO HCC_NP in_IN Japan_NP ._SENT 